Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$18.08 - $25.38 $7,231 - $10,152
400 Added 3.01%
13,700 $317,000
Q2 2024

Aug 14, 2024

BUY
$24.35 - $44.39 $63,310 - $115,414
2,600 Added 24.3%
13,300 $323,000
Q1 2024

May 15, 2024

SELL
$31.23 - $42.99 $384,129 - $528,777
-12,300 Reduced 53.48%
10,700 $361,000
Q4 2023

Feb 14, 2024

BUY
$17.71 - $32.97 $159,390 - $296,730
9,000 Added 64.29%
23,000 $725,000
Q3 2023

Nov 14, 2023

SELL
$25.44 - $37.35 $318,000 - $466,875
-12,500 Reduced 47.17%
14,000 $357,000
Q2 2023

Aug 14, 2023

BUY
$23.94 - $32.36 $172,368 - $232,992
7,200 Added 37.31%
26,500 $760,000
Q1 2023

May 15, 2023

BUY
$14.72 - $23.97 $54,464 - $88,689
3,700 Added 23.72%
19,300 $462,000
Q4 2022

Feb 14, 2023

BUY
$14.14 - $23.06 $220,584 - $359,736
15,600 New
15,600 $264,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $411M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.